Michael Seaman, Ph.D.

Education

• University of Washington, Seattle, WA, B.S., 1992 (Microbiology)
• University of Texas Southwestern Medical Center, Dallas, TX, Ph.D., 2000 (Immunology)

Training

• Research Fellow, Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Boston, MA, 2004 (Immunology)

Appointments

• 1992-1994, Research Assistant I and II, Department of Immunobiology, Immunex Corporation, Seattle, WA
• 2004-2007, Instructor in Medicine, Harvard Medical School, Boston, MA
• 2007-2017, Assistant Professor of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
• 2017- present, Associate Professor of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

Honors

• 1996-1999, NRSA Predoctoral Trainee, NIH #5 T32 CA09082
• 2000-2002, NRSA Fellow, Postdoctoral Training Program in AIDS Research (Dana-Farber Cancer Institute, NIH #5 T32 AI07386)
• 2008, Network Citizenship Award, NIH HIV Vaccine Trials Network (HVTN)
• 2012, Young/Early Career Investigator Award, Collaboration for AIDS Vaccine Development (CAVD)

Publications

• Stephenson KE, Le Gars M, Sadoff J, de Groot AM, Heerwegh D, Truyers C, Atyeo C, Loos C, Chandrashekar A, McMahan K, Tostanoski LH, Yu J, Gebre MS, Jacob-Dolan C, Li Z, Patel S, Peter L, Liu J, Borducchi EN, Nkolola JP, Souza M, Tan CS, Zash R, Julg B, Nathavitharana RR, Shapiro RL, Azim AA, Alonso CD, Jaegle K, Ansel JL, Kanjilal DG, Guiney CJ, Bradshaw C, Tyler A, Makoni T, Yanosick KE, Seaman MS, Lauffenburger DA, Alter G, Struyf F, Douoguih M, Van Hoof J, Schuitemaker H, Barouch DH. Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. JAMA. 2021 Mar 11:e213645. doi: 10.1001/jama.2021.3645. Epub ahead of print. PMID: 33704352; PMCID: PMC7953339. [Article]


• Xiao T, Lu J, Zhang J, Johnson RI, McKay LGA, Storm N, Lavine CL, Peng H, Cai Y, Rits-Volloch S, Lu S, Quinlan BD, Farzan M, Seaman MS, Griffiths A, Chen B. A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent. Nat Struct Mol Biol. 2021 Feb;28(2):202-209. doi: 10.1038/s41594-020-00549-3. Epub 2021 Jan 11. PMID: 33432247; PMCID: PMC7895301.
  [Article]


• Edlow AG, Li JZ, Collier AY, Atyeo C, James KE, Boatin AA, Gray KJ, Bordt EA, Shook LL, Yonker LM, Fasano A, Diouf K, Croul N, Devane S, Yockey LJ, Lima R, Shui J, Matute JD, Lerou PH, Akinwunmi BO, Schmidt A, Feldman J, Hauser BM, Caradonna TM, De la Flor D, D'Avino P, Regan J, Corry H, Coxen K, Fajnzylber J, Pepin D, Seaman MS, Barouch DH, Walker BD, Yu XG, Kaimal AJ, Roberts DJ, Alter G. Assessment of Maternal and Neonatal SARS-CoV-2 Viral Load, Transplacental Antibody Transfer, and Placental Pathology in Pregnancies During the COVID-19 Pandemic. JAMA Netw Open. 2020 Dec 1;3(12):e2030455. doi: 10.1001/jamanetworkopen.2020.30455. PMID: 33351086; PMCID: PMC7756241. [Article]


• Tartaglia LJ, Gupte S, Pastores KC, et al. Differential Outcomes following Optimization of Simian-Human Immunodeficiency Viruses from Clades AE, B, and C. J Virol. 2020;94(10):e01860-19. Published 2020 May 4. doi:10.1128/JVI.01860-19 [Article]


• Silver ZA, Dickinson GM, Seaman MS, Desrosiers RC. A Highly Unusual V1 Region of Env in an Elite Controller of HIV Infection. J Virol. 2019 May 15;93(10). doi: 10.1128/JVI.00094-19. [Article]


• Schoofs T, Barnes CO, Suh-Toma N, Golijanin J, Schommers P, Gruell H, West AP Jr, Bach F, Lee YE, Nogueira L, Georgiev IS, Bailer RT, Czartoski J, Mascola JR, Seaman MS, McElrath MJ, Doria-Rose NA, Klein F, Nussenzweig MC, Bjorkman PJ. Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope. Immunity. 2019 Jun 18;50(6):1513-1529.e9. [Article]


• Han Q, Jones JA, Nicely NI, Reed RK, Shen X, Mansouri K, Louder M, Trama AM, Alam SM, Edwards RJ, Bonsignori M, Tomaras GD, Korber B, Montefiori DC, Mascola JR, Seaman MS, Haynes BF, Saunders KO. Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations. Nat Commun. 2019 Jul 1;10(1):2898. [Article]


• Kerwin BA, Bennett C, Brodsky Y, Clark R, Floyd JA, Gillespie A, Mayer BT, McClure M, Siska C, Seaman MS, Seaton KE, Shaver J, Tomaras GD, Yates NL, Ketchem RR. Framework mutations of the 10-1074 bnAb increase conformational stability, manufacturability and stability while preserving full neutralization activity. J Pharm Sci. 2019 Jul 23;. doi: 10.1016/j.xphs.2019.07.009. [Epub ahead of print]. [Article]


• Bricault CA, Yusim K, Seaman MS, Yoon H, Theiler J, Giorgi EE, Wagh K, Theiler M, Hraber P, Macke JP, Kreider EF, Learn GH, Hahn BH, Scheid JF, Kovacs JM, Shields JL, Lavine CL, Ghantous F, Rist M, Bayne MG, Neubauer GH, McMahan K, Peng H, Chéneau C, Jones JJ, Zeng J, Ochsenbauer C, Nkolola JP, Stephenson KE, Chen B, Gnanakaran S, Bonsignori M, Williams LD, Haynes BF, Doria-Rose N, Mascola JR, Montefiori DC, Barouch DH*, Korber B*. HIV-1 neutralizing antibody signatures and application to epitope-targeted vaccine design. Cell Host Microbe 2019; 25:59-72. [Article]


• Hartweger H, McGuire AT, Horning M, Taylor JJ, Dosenovic P, Yost D, Gazumyan A, Seaman MS, Stamatatos L, Jankovic M, Nussenzweig MC. HIV-specific humoral immune responses by CRISPR/Cas9-edited B cells. J Exp Med. 2019 Jun 3;216(6):1301-1310. [Article]